Physician profile
Malia Beth Dimeling
NPI 1417771445
$981.20
in general payments reported to CMS, 2019-2025
27 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $114.22 | 2025 | Libtayo, Lynozyfic |
| Merck Sharp & Dohme LLC | $83.07 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $70.66 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $55.83 | 2025 | Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.32 | 2025 | |
| Sumitomo Pharma America, INC. | $48.60 | 2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $46.83 | 2025 | Iclusig, Ninlaro |
| Alnylam Pharmaceuticals INC. | $42.81 | 2025 | Givlaari |
| Glaxosmithkline, LLC. | $40.38 | 2025 | Ojjaara, Blenrep |
| Bayer Healthcare Pharmaceuticals INC. | $38.37 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.26 | 2025 | Opdivo |
| Janssen Biotech, INC. | $34.45 | 2025 | Carvykti, Darzalex, Talvey |
| Blueprint Medicines Corporation | $33.41 | 2025 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $33.38 | 2025 | |
| Legend Biotech USA INC. | $24.44 | 2025 | Carvykti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $22.32 | 2025 | Epkinly |
| Incyte Corporation | $21.90 | 2025 | Monjuvi, Zynyz |
| Lilly USA, LLC | $20.21 | 2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $19.92 | 2025 | Trodelvy |
| Genzyme Corporation | $19.25 | 2025 | |
| Genentech USA, INC. | $18.75 | 2025 | Lunsumio |
| Abbvie INC. | $18.53 | 2025 | |
| Caris Mpi, INC. | $17.41 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $16.96 | 2025 | Xalkori |
| Eisai INC. | $16.69 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.67 | 2025 | Danziten, Vivimusta |
| Novocure INC. | $14.56 | 2025 | Optune Gio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malia Dimeling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.